Potential peripartum markers of infectious-inflammatory complications in spontaneous preterm birth

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Tambor, Vojtech ^a,c   Vajrychova, Marie ^b   Kacerovsky, Marian ^a   Link, Marek ^b   Domasinska, Petra ^a   Menon, Ramkumar ^d   Lenco, Juraj ^b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCALIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLACENTA PROTEIN 14; PROTEOME;

AMNION FLUID; AMNION FLUID ANALYSIS; AMNIONITIS; ARTICLE; DELIVERY; DISEASE MARKER; FEMALE; HUMAN; INFECTION; INFLAMMATION; LABOR; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN MORBIDITY; NUCLEOTIDE SEQUENCE; PERINATAL PERIOD; PREGNANCY COMPLICATION; PREMATURE LABOR; STRESS; TANDEM MASS SPECTROMETRY; ADULT; COMPLICATION; GENETICS; METABOLISM; PATHOLOGY; PEPTIDE MAPPING; PREGNANCY; PREMATURITY;

ADULT; AMNIOTIC FLUID; FEMALE; HUMANS; INFLAMMATION; PEPTIDE MAPPING; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; PROTEOME;

EID: 84930683212     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/343501     Document Type: Article

References (41)

1. World Health Organization, "The prevention of perinatal mortality and morbidity. Report of a WHO Expert Committee," World Health Organization Technical Report Series 457,World Health Organization, Geneva, Switzerland, 1970.
2. M. L. Wang, D. J. Dorer, M. P. Fleming, and E. A. Catlin, "Clinical outcomes of near-terminfants," Pediatrics, vol. 114, no. 2, pp. 372-376, 2004.
3. R. L. Goldenberg, J. F. Culhane, J. D. Iams, and R. Romero, "Epidemiology and causes of preterm birth," The Lancet, vol. 371, no. 9606, pp. 75-84, 2008.
4. J. A. Martin, B. E. Hamilton, S. J. Ventura et al., "Births: final data for 2009," National Vital Statistics Reports, vol. 60, no. 1, pp. 1-70, 2011.
5. C. L. J. Huddy, A. Johnson, and P. L. Hope, "Educational and behavioural problems in babies of 32-35 weeks gestation," Archives of Disease in Childhood, vol. 85, no. 1, pp. F23-F28, 2001.
6. J.-M. Moutquin, "Classification and heterogeneity of preterm birth," BJOG, vol. 110, supplement 20, pp. 30-33, 2003.
7. N.-H. Morken, P. Magnus, and B. Jacobsson, "Subgroups of preterm delivery in the Norwegian Mother and Child Cohort Study,"ActaObstetricia etGynecologicaScandinavica, vol. 87,no. 12, pp. 1374-1377, 2008.
8. N.-H. Morken, I. Vogel, K. Kallen et al., "Reference population for international comparisons and time trend surveillance of pretermdelivery proportions in three countries,"BMCWomen's Health, vol. 8, article 16, 2008.
9. D. R. Mattison, K. Damus, E. Fiore, J. Petrini, and C. Alter, "Preterm delivery: A public health perspective," Paediatric and Perinatal Epidemiology, vol. 15, supplement 2, pp. 7-16, 2001.
10. R. L. Goldenberg, J. C. Hauth, andW. W. Andrews, "Intrauterine infection and preterm delivery," The New England Journal of Medicine, vol. 342, no. 20, pp. 1500-1507, 2000.
11. H. Iguchi, S. Natori, and H. Nawata, "Effect of GRF and somatostatin on 7B2 secretion by rat GH1 cells," Endocrinologia Japonica, vol. 36, no. 6, pp. 787-793, 1989.
12. T. E. Angel,U. K. Aryal, S. M. Hengel et al., "Mass spectrometrybased proteomics: existing capabilities and future directions," Chemical Society Reviews, vol. 41, no. 10, pp. 3912-3928, 2012.
13. V. Tambor, C. L. Hunter, S. L. Seymour, M. Kacerovsky, J. Stulik, and J. Lenco, "CysTRAQ-a combination of iTRAQ and enrichment of cysteinyl peptides for uncovering and quantifying hidden proteomes," Journal of Proteomics, vol. 75, no. 3, pp. 857-867, 2012.
14. V. Tambor, A. Fućková, J. Lenco et al., "Application of proteomics in biomarker discovery: A primer for the clinician," Physiological Research, vol. 59, no. 4, pp. 471-497, 2010.
15. T. Shi, D. Su, T. Liu et al., "Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics," Proteomics, vol. 12, no. 8, pp. 1074-1092, 2012.
16. T. T. Aye, T. Y. Low, Y. Bjørlykke, H. Barsnes, A. J. R. Heck, and F. S. Berven, "Use of stable isotope dimethyl labeling coupled to selected reaction monitoring to enhance throughput by multiplexing relative quantitation of targeted proteins," Analytical Chemistry, vol. 84, no. 11, pp. 4999-5006, 2012.
17. W. H. Tang, I. V. Shilov, and S. L. Seymour, "Nonlinear fitting method for determining local false discovery rates from decoy database searches," Journal of Proteome Research, vol. 7, no. 9,pp. 3661-3667, 2008.
18. I. V. Shilov, S. L. Seymourt, A. A. Patel et al., "The paragon algorithm, a next generation search engine that uses sequence temperature values sequence temperature values and feature probabilities to identify peptides from tandem mass spectra," Molecular and Cellular Proteomics, vol. 6, no. 9, pp. 1638-1655, 2007.
19. B. MacLean, D. M. Tomazela, N. Shulman et al., "Skyline: aAn open source document editor for creating and analyzing targeted proteomics experiments," Bioinformatics, vol. 26, no. 7, Article ID btq054, pp. 966-968, 2010.
20. V. Tambor, M. Kacerovsky, C. Andrys et al., "Amniotic fluid cathelicidin in pprom pregnancies: from proteomic discovery to assessing its potential in inflammatory complications diagnosis," PLoS ONE, vol. 7, no. 7,Article ID e41164, 2012.
21. E. Bujold, R. Romero, J. P. Kusanovic et al., "Proteomic profiling of amniotic fluid in pretermlabor using two-dimensional liquid separation and mass spectrometry," Journal of Maternal-Fetal and Neonatal Medicine, vol. 21, no. 10, pp. 697-713, 2008.
22. I. A. Buhimschi, R. Christner, and C. S. Buhimschi, "Proteomic biomarker analysis of amniotic fluid for identification of intraamniotic inflammation," BJOG: An International Journal of Obstetrics and Gynaecology, vol. 112, no. 2, pp. 173-181, 2005.
23. M. G. Gravett, M. J. Novy, R. G. Rosenfeld et al., "Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers," Journal of the American Medical Association, vol. 292, no. 4, pp. 462-469, 2004.
24. C. Evans, J. Noirel, S. Y. Owet al., "Aninsight into iTRAQ: where do we stand now" Analytical and Bioanalytical Chemistry, vol. 404, no. 4, pp. 1011-1027, 2012.
25. M. Kacerovsky, V. Tambor, M. Vajrychová et al., "Amniotic fluid myeloperoxidase in pregnancies complicated by preterm prelabor rupture of membranes," Journal of Maternal-Fetal and Neonatal Medicine, vol. 26, no. 5, pp. 463-468, 2013.
26. M. Hayashi, K. Zhu, T. Sagesaka, I. Fukasawa, and N. Inaba, "Elevation of amniotic fluid macrophage colony-stimulating factor in normotensive pregnancies that delivered small-forgestational-age infants," American Journal of Reproductive Immunology, vol. 57, no. 6, pp. 488-494, 2007.
27. D. Kovanich, S. Cappadona, R. Raijmakers, S. Mohammed, A. Scholten, and A. J. R. Heck, "Applications of stable isotope dimethyl labeling in quantitative proteomics," Analytical and Bioanalytical Chemistry, vol. 404, no. 4, pp. 991-1009, 2012.
28. A. J. Percy, A. G. Chambers, J. Yang, D. Domanski, and C. H. Borchers, "Comparison of standard-and nano-flowliquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins," Analytical and Bioanalytical Chemistry, vol. 404, no. 4, pp. 1089-1101, 2012.
29. B. Ericksen, Z. Wu,W. Lu, andR. I. Lehrer, "Antibacterial activity and specificity of the six human -defensins," Antimicrobial Agents and Chemotherapy, vol. 49, no. 1, pp. 269-275, 2005.
30. D. A. Dartt, "Tear lipocalin: structure and function," Ocular Surface, vol. 9, no. 3, pp. 126-138, 2011.
31. B. J. Glasgow and O. K. Gasymov, "Focus on molecules: tear lipocalin," Experimental Eye Research, vol. 92, no. 4, pp. 242-243, 2011.
32. W. van't Hof, M. F. J. Blankenvoorde, E. C. I. Veerman, and A. V. Nieuw Amerongen, "Thesalivary lipocalin von Ebner's gland protein is a cysteine proteinase inhibitor," Journal of Biological Chemistry, vol. 272, no. 3, pp. 1837-1841, 1997.
33. M. Seppälä, R. N. Taylor, H. Koistinen, R. Koistinen, and E. Milgrom, "Glycodelin: A major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation," Endocrine Reviews, vol. 23, no. 4, pp. 401-430, 2002.
34. C. L. Lee, K. K. W. Lam, H. Koistinen et al., "Glycodelin-A as a paracrine regulator in early pregnancy," Journal of Reproductive Immunology, vol. 90, no. 1, pp. 29-34, 2011.
35. M. Julkunen, E.-M. Rutanen, A. Koskimies, T. Ranta, H. Bohn, and M. Seppälä, "Distribution of placental protein 14 in tissues and body fluids during pregnancy," BJOG, vol. 92, no. 11, pp. 1145-1151, 1985.
36. G. Oggé, R. Romero,D.-C. Lee et al., "Chronic chorioamnionitis displays distinct alterations of the amniotic fluid proteome," Journal of Pathology, vol. 223, no. 4, pp. 553-565, 2011.
37. B. Samal, Y. Sun, G. Stearns, C. Xie, S. Suggs, and I. Mcniece, "Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor," Molecular and Cellular Biology, vol. 14, no. 2, pp. 1431-1437, 1994.
38. C. Hug and H. F. Lodish, "Visfatin: A new adipokine," Science, vol. 307, no. 5708, pp. 366-367, 2005.
39. S. Mazaki-Tovi, R. Romero, J. P. Kusanovic et al., "Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition," Journal of Perinatal Medicine, vol. 36, no. 6, pp. 485-496, 2008.
40. C. E. Kendal and G. D. Bryant-Greenwood, "Pre-B-cell colonyenhancing factor (PBEF/Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells," Placenta, vol. 28, no. 4, pp. 305-314, 2007.
41. S. Ognjanovic, S. Bao, S. Y. Yamamoto, J. Garibay-Tupas, B. Samal, andG. D. Bryant-Greenwood, "Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes," Journal of Molecular Endocrinology, vol. 26, no. 2, pp. 107-117, 2001.